Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bempedoic Acid in Patients With Hyperlipidemia Not Adequately Controlled by Statins
NCT07623915Phase 3Not yet recruiting
- Sponsor
- CSPC Ouyi Pharmaceutical
- Start
- Jun 2026
- Primary completion
- Jun 2027
01
Overview
Phase 3, randomised, double-blind trial in primary hyperlipidemia comparing Bempedoic Acid Tablet with Placebo (2 arms). Primary endpoint: Percentage change from baseline in LDL-C levels at 12 weeks. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
bempedoic acid
03
Conditions
primary hyperlipidemia
Beyond the preview
Go deeper on NCT07623915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07623915.